康方生物-B(09926.HK)彈逾5% 獲里昂升目標價兼重申「買入」
康方生物-B(09926.HK)扭兩連跌,今日(9日)高開0.9%,報45.8元後升幅擴大,最高見48.5元,一度逼近上周三(6日)所創逾一年高位(49.4元)。現報47.85元,反彈5.4%,成交859.12萬股,涉資4.09億元。
里昂發表報告,指料公司去年錄收入增至8.23億元人民幣,淨虧損11.72億元人民幣,源於推出cadonilimab及PD-1銷售進一步增加。該行料公司今年銷售進一步增加,受惠核心藥品銷售加快、交易前置收入貢獻,以及豐富的產品線帶來催化劑。
該行喜好其具質素的管理團隊,強勁免疫腫瘤學(I/O)雙特異性抗體(BsAb)特許經營權,以及海外發展帶來長遠上行空間。該行修訂對其盈虧預測,以現金流折現率計,目標價由40.9元升至57.8元,重申「買入」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.